MENU

FDA OKs heart drug at center of $13 billion deal for Peninsula company

MyoKardia, co-founded by a Stanford University professor, developed the drug as part of a portfolio of treatments for genetic heart conditions.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
TOP
Email a Story